Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality |
| |
Authors: | Bobbie Ann Austin Cassandra M James Peter Härle Daniel J J Carr |
| |
Institution: | (1) Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA;(2) Division of Veterinary & Biomedical Health Science, Murdoch University, 6150 Perth, Australia;(3) Laboratory of Neuroendocrinoimmunology, University Medical Center, 93053 Regensburg, Germany;(4) Departments of Ophthalmology and Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA |
| |
Abstract: | The application of naked DNA containing type I interferon (IFN) transgenes is a promising potential therapeutic approach for
controlling chronic viral infections. Herein, we detail the application of this approach that has been extensively used to
restrain ocular HSV-1 infection, for antagonizing vaginal HSV-2 infection. We show that application of IFN-α1, -α 5, and -β
transgenes to vaginal mouse lumen 24 hours prior to HSV-2 infection reduces HSV-2 mediated mortality by 2.5 to 3-fold. However,
other type I IFN transgenes (IFN- α 4, -α 5, -α 6, and -α 9) are non effectual against HSV-2. We further show that the efficacy
of IFN-1 transgene treatment is independent of CD4+ T lymphocytes. However, in mice depleted of CD8+ T lymphocytes, the ability
of IFN-α 1 transgene treatment to antagonize HSV-2 was lost. |
| |
Keywords: | Indexing terms" target="_blank">Indexing terms Virus Interferon T-lymphocyte Transgene |
本文献已被 SpringerLink 等数据库收录! |
|